Advertisement

Harvest Technologies Corp. receives expanded CE Mark approval for its SmartPReP2 bone marrow aspiration concentration system product for treating no-option critical limb ischemia.

Harvest logo

Plymouth, Mass.-based cellular therapy manufacturer Harvest Technologies landed expanded CE Mark approval for its bone marrow aspiration concentration system product in point-of-care cell concentrate preparation for treatment of no-option critical limb ischemia.

Clinical studies used to support expanded CE Mark showed that the BMAC2 system could reduce risk for amputation as well as improve "rest pain" in patients with critical limb ischemia, according to the company.

Advertisement
Advertisement